Summary
Renal insufficiency is characterised by impaired host defences, which are compromised further by each of the 3 modes of renal replacement — haemodialysis, continuous ambulatory peritoneal dialysis (CAPD) and renal transplantation. Reduced renal clearance of unknown toxins, possible development of nutritional deficiencies and administration of immunosuppressive medications lead to aberrant immune regulation early in the course of renal failure. This results subsequently in increased frequency and severity of infection. Vaccination plays an important role in attenuating this infection risk, but impaired cell-mediated and humoral immunity contraindicates the use of live vaccines and engenders suboptimal and short-lived antibody responses to inactivated vaccines. Reinforced vaccination schedules, increased vaccine dosage and concomitantly administered adjuvant immunomodulators have variably improved the defective antibody responses to certain vaccines.
Immunisation against hepatitis B virus has resulted in a significant decrease in prevalence and incidence of this infection in haemodialysis units. Similarly, the inoculation of influenza vaccine in patients with uraemia and of polyvalent pneumococcal vaccine in special risk circumstances has been recommended because of perceived reductions in morbidity and mortality from infection with these agents. Cytomegalovirus (CMV) vaccine may attenuate CMV disease severity in recipients of renal allografts. Staphylococcus aureus vaccine, on the other hand, is ineffective in preventing peritonitis or exit site infections in patients receiving CAPD. Other killed vaccines have not been comprehensively studied, but generally have the same indications for use as in normal individuals. However, the protection that these vaccines afford may be either inadequate or transient, so that other infection control strategies should be simultaneously implemented.
Similar content being viewed by others
References
Abrutyn E, Solomon NW, St Clair L, Mac Gregor RR, Root RK. Granulocyte function in patients with chronic renal failure: surface adherence, phagocytosis and bacterial activity in vitro. Journal of Infectious Diseases 135: 1–8, 1977
Albert FW, Brisam A, Traut G, Thamer G. E antigen in the serum of HBsAg-positive patients on maintenance haemodialysis and after transplantation. Proceedings of the European Dialysis and Transplantation Society 15: 306–311, 1978
Alter MJ, Farrero MS, Maynard JG. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. Journal of Infectious Diseases 153: 1149–1151, 1986
Alter MJ, Farrero MS, Peterson NO, Dotci L, Legger RT, et al. National surveillance of dialysis-associated diseases in the United States, 1988. American Society for Artificial Internal Organs Transactions 36: 107–117, 1990
Andrew OT, Schoenfield PT, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. American Journal of Medicine 68: 59, 1980
Aronoff GR, Maxwell DR, Batteiger BE, Fineberg NS. Hepatitis B vaccine: a randomized trial of a reduced regimen in haemodialysis patients. American Journal of Kidney Disease 6: 170–172, 1985
Australia and New Zealand Dialysis and Transplant Registry. Thirteenth Report of the ANZDATA Registry (APS Disney Ed.), Queen Elizabeth Hospital, South Australia, June 1990
Balch HH. The effect of severe battle injury and of post-traumatic renal failure on resistance to infection. Annals of Surgery 142: 145–163, 1955
Bass HE, Greenberg D, Singer E, Mitler MA. Pulmonary changes in uraemia. Journal of the American Medical Association 148: 724–726, 1952
Baum J, Cestero RVM, Freeman RB. Chemotaxis of the polymorphonuclear leucocyte and delayed hypersensitivity in uraemia. Kidney International 2 (Suppl.): 5147–5153, 1975
Beauman M, Michael J, MacLennon IC, Aolu S. T-Cell-independent and T-Cell-dependent antibody responses in patients with chronic renal failure. Nephrology Dialysis Transplantation 4: 216–221, 1989
Benhamou G, Courouce AM, Jungers P. Hepatitis B vaccine: randomized trial of immunogenicity in haemodialysis patients. Clinical Nephrology 21: 143, 1984
Beurain G, Naret C, Marcon L, Grateau G, Drucke T, et al. In vivo T cell preactivation in chronic uraemic haemodialyzed and non-haemodialyzed patients. Kidney International 36: 636–644, 1989
Beyer WE, Versluis SJ, Kramer P, Diderich PP, Weimar M, et al. Trivalent influenza vaccine in patients on haemodialysis: impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components. Vaccine 5: 43–48, 1987
Beyer WEP, Noorolzy TC, Kramer P, Diderich PPMN, Opden Hook CT, et al. Effect of immunomodulator thymopentin on impaired seroresponse to influenza vaccine in patients on haemodialysis. Nephron 54: 296–304, 1990
Blagg CR, Tenckhoff H. Microbial contamination of water used for haemodialysis. Nephron 15: 81–86, 1975
Bolla K, Cappel R, Duchateau J. Activation of peripheral blood lymphocytes as a potential basic mechanism of immunomodulation. International Journal of Immunopharmacology 3: 71–79, 1987
Bommer J, Grussendorf M, Jilg W, Reinhardt F, Kock HG, et al. Vaccination against hepatitis B in patients with renal insufficiency. Proceedings of the European Dialysis and Transplant Association 21: 300–305, 1984
Bommer J, Ritz G, Andrassy K. Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proceedings of the European Dialysis and Transplantation Association 20: 161–166, 1983
Bramwell SP, Briggs JS, Stewart J, Watson MA, Toasiros DJ, et al. Dinitrochlorobenzene skin testing predicts response to hepatitis B vaccine in dialysis patients. Lancet 2: 1412–1415, 1985
Brenner BM, Lazarus JM. Chronic renal failure. In Isselbacher et al. (Eds) Harrison’s principles of internal medicine, 11th ed., pp. 1151–1157, McGraw Hill, New York, 1990
Briggs WA, Dale HS, Mahojan SS, McDonald FD. Leucocyte metabolism and function in uraemia. Kidney International 24 (Suppl.): 593, 1983
Briggs WA, Razek RJ, Megidal SD, Shillis JL, Brackett RG, et al. Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. Annals of Internal Medicine 92: 471, 1980
Brogan TD. Phagocytosis by polymorphonuclear leukocytes from patients with renal failure. British Medical Journal 3: 596, 1967
Broyer M, Boudouillez F. Varicella vaccine in children with chronic renal insufficiency. Postgraduate Medical Journal 61 (Suppl. 4): 103–106, 1985
Bruguera M, Cremades M, Rodicio JL, Alcazar JM, Olives A, et al. Immunogenicity of a yeast-derived hepatitis B vaccine in haemodialysis patients. American Journal of Medicine 87 (Suppl. 3a): 305–325, 1989
Cappel R, Van Beers D, Liesnard C, Dratura M. Impaired humoral and cell-mediated responses in dialyzed patients after influenza vaccination. Nephron 33: 21–25, 1983
Carpenter CB, Lazarus JM. Dialysis and transplantation in the treatment of renal failure. In Isselbacher et al. (Eds) Harrison’s principles of internal medicine, 11th ed., pp. 1157–1166, McGraw Hill, New York, 1990
Carpenter CB, Milford EL. Renal transplantation: immunobiology. In Brenner & Rector (Eds.) The kidney, 3rd ed., p. 107, Saunders, Philadelphia, 1986
Carreno V, Mora I, Escuin F, Sanchez-Sicilia L, Alvarez V, et al. Vaccination against hepatitis B in renal dialysis units: short or normal vaccination schedule? Clinical Nephrology 24: 215–220, 1985
Carroll RNP, Marsh SD, O’Donoghue EPN, Breeze DC, Slackman R. Response to influenza vaccine by renal transplant patients. British Medical Journal 2: 701, 1974
Casciani CV, de Simone C, Bonini S, et al. Immunological aspects of chronic uraemia. Kidney International 8 (Suppl.): 549–554, 1978
Centers for Disease Control. Control measures for hepatitis in dialysis centres, Viral Hepatitis Investigations and Control Series, Atlanta, Georgia, November 1977
Centers for Disease Control. Prevention and control of influenza. Morbidity and Mortality Weekly Report 38: 297, 1989
Chatenoud L, Dugas B, Beurain G, Touan M, Drucke T, et al. Presence of preactivated T cells in haemodialyzed patients: their possible role in altered immunity. Proceedings of the National Academy of Science USA 83: 7457–7461, 1986
Cordier G, Brochier J, Revillard JP. Cytotoxic and proliferative responses of human thoracic duct lymphocytes: effect of thoracic duct drainage in uraemic patients. Clinical Immunology and Immunopathology 5: 351–359, 1976
Crosnier J, Jungers P, Couroce AM, Laplancle A, Benhamou E, et al. Randomized placebo controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: haemodialysis patients. Lancet 1: 797–800, 1981
Dammin GJ, Couch NP, Murray JE. Prolonged survival of skin homografts in uraemic patients. Annals of the New York Academy of Science 64: 967–976, 1956
Dentico P, Volpe A, Zavoinni A. Safety and efficacy of a yeast-derived hepatitis B vaccine in haemodialysis patients. Abstract 261. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston, Texas, April 4–8, 1990
Desmyter J, Colaert J, De Groote G, Reynders M, Reering-Brongers GG, et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Lancet 2: 1323–1327, 1983
Dobbelstein H. Immune system in uraemia. Nephron 17: 409–415, 1976
Docci D, Cipolloni PA, Baldrati L, Capponcini C, Turci G, et al. Immune response to a recombinant hepatitis B vaccine in haemodialysis patients. International Journal of Artificial Organs 13: 451–453, 1990
Donati C, Castaldi L. Controlled trial of thymopentin in haemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 50: 133–136, 1988
Douglas RC. Prevention, management and control of influenza — a mandate for the 1980’s. American Journal of Medicine 6A (Suppl.): 82, 1987
Duchateau J, Servais G, Cooman R, Collett H, Bolla K. In vitro influence of thymopentin on proliferative responses and phytohaemagglutinin-induced interleukin-2 production in normal lymphocyte cultures. Surveys of Immunologic Research 4 (Suppl.): 116–124, 1985
Dumann H, Meuer S, Meyer zum Buschenfelde KH, Kohler H. Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure. Kidney International 38: 1164–1168, 1990a
Dumann H, Meuer S, Renschin G, Kohler H. Influence of thymopentin on antibody response, and monocyte and T cell function in haemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 55: 136–140, 1990b
Eickhoff TC, Sherman IL, Serfing RE. Observations on excess mortality associated with epidemic influenza. Journal of the American Medical Association 176–782, 1961
Elves MW, Israels MCG, Collinge M. An assessment of the mixed leucocyte reaction in renal failure. Lancet 1: 682–685, 1966
Feldhoff C, Balfour H, Simmons R, Najarian J, Mauer M. Varicella in children with renal transplants. Journal of Paediatrics 98: 25, 1981
Fleming SJ, Moran DM, Cooksley WGE, Faoagoli JL. Poor response to a recombinant hepatitis B vaccine in dialysis patients. Journal of Infection 22: 251–257, 1991
Fujiyama S, Yoshida K, Sato T, Shimada H, Deguchi T. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients. Hepatogastroenterology 37 (Suppl.): 140–144, 1990
Furlan A, Schinela D, Galo E, Santarossa L. Anti-HBs response in haemodialysis patients to DNA recombinant anti-HBV vaccine. Abstract 260. 1990 International Symposium on Viral Hepatitis and Liver Disease,Houston, Texas, April 4–8, 1990
Giacchino F, Quarello F, Pellerey M, Piccoli G. Continuous ambulatory peritoneal dialysis improves immunodeficiency in uraemic patients. Nephron 35: 209–210, 1983
Glenn J. Cytomegalovirus infections following renal transplantation. Reviews of Infectious Disease 3: 1151–1178, 1981
Giordano D, Le Santo NG, Cirillo D, Perna N. Skin exfoliation after renal failure. British Medical Journal 4: 179, 1972
Goldblum SE, Reed WP. Host defences and immunologic alterations associated with chronic haemodialysis. Annals of Internal Medicine 93: 597–612, 1980
Goldstein E, Green GM. The effect of acute renal failure on the bacterial clearance mechanisms of the lung. Journal of Laboratory and Clinical Medicine 68: 531–542, 1966
Goldstein G, Ausllyo TK. Thymopoietin to thymopentin: experimental studies. Surveys of Immunologic Research 4 (Suppl. 1): 1–10, 1985
de Graeff PA, Dankert J, de Zeeuiv F, Gips CH, vom der Hem GK. Immune responses to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. Nephron 40: 155–160, 1985
Grob P. Hepatitis B vaccination of renal transplant and haemodialysis patients. Scandinavian Journal of Infectious Diseases 38 (Suppl.): 28–32, 1983
Grob PJ, Ambrosch F, Courouce AM. Immunisation against hepatitis B. Lancet 1: 875–876, 1988
Grob PJ, Binswanger V, Blumberg A, Gloor HJ, Hony A, et al. Thymopentin as adjuvant to hepatitis B vaccination: results from three double-blind studies. Surveys of Immunologic Research 4 (Suppl. 1): 107–115, 1985
Grob PJ, Joller-Jemelka HI, Binsuranger V, Zaruba K, Descosudres C, et al. Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations. European Journal of Clinical Microbiology 3: 195–198, 1984
Guillov PJ, Woodhouse LF, Davidson AM, Giles GR. Suppressor cell activity of peripheral mononuclear cells from patients undergoing chronic haemodialysis. Biomedicine 32: 11–17, 1980
Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. New England Journal of Medicine 315: 209–214, 1986
Ho M, Wajegouck CP, Hardy A. Infections in kidney, heart and liver transplant recipients on cyclosporine. Transplantation Proceedings 15; 2768–2672, 1983
Hosking CS, Atkins RC, Scott DF, Holdsworth SR, Fitzgerald MG, et al. Immune and phagocyte functions in patients on maintenance dialysis and post-transplantation. Clinical Nephrology 6: 501–505, 1976
Hoy WE, Cestero RVM, Freeman RB. Deficiency of T and B lymphocytes in uraemic subjects and partial improvement with maintenance haemodialysis. Nephron 20: 182–188, 1978
Hurwich BJ, Chait A, Dollberg M, Dollberg L. Malignancy in chronic renal failure. Lancet 2: 716, 1975
Jaffe RH, Laing DR. Changes of the digestive tract in uraemia: a pathologic anatomic study. Archives of Internal Medicine 53: 851–864, 1934
Jilg W, Deinhardt F. Results of immunisation with a recombinant yeast-derived hepatitis B vaccine. Journal of Infection 13: 47–51, 1986
Jilg W, Schmidt M, Deinhardt F, Zacharal R. Hepatitis B vaccination: how long does protection last? Lancet 2: 458, 1984
Jilg W, Schmidt M, Weirel B. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. Journal of Hepatology 3: 190–195, 1986
Johnstone MFM, Slavin RG. Mechanism of inhibition of adoptive transfer to tuberculin sensitivity in acute uraemia. Journal of Laboratory and Clinical Medicine 87: 457–461, 1976
Jonston RB. Current concepts — immunology: monocytes and macrophages. New England Journal of Medicine 318: 747–752, 1988
Kasakura S, Lowenstein L. The effect of uraemic blood on mixed leucocyte reactions and on cultures of leucocytes with phytohaemagglutinin. Transplantation 5: 283–289, 1967
Keane WF, Shapiro FL, Raji L. Incidence and type of infections occurring in 445 chronic haemodialysis patients. Transactions of the American Society of Artificial Internal Organs 23: 41–46, 1977
Kidd EE. Bacterial contamination of dialysing fluid of artificial kidney. British Medical Journal 1: 880–882, 1964
Kirkpatrick CH, Wilson WEC, Talmage DW. Immunology studies in human organ transplantation I: observation and characterization of suppressed cutaneous reactivity in uraemia. Journal of Experimental Medicine 119: 727–742, 1964
Kjellstrand CM. Are malignancies increased in uraemia? Nephron 23: 159–161, 1979
Kohler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney International 29: 124–128, 1984
Kohler H, Dumann H, Meyer zum Buschenfelde KH, Meuer S. Sekundarer Immundefekt bei Niereninsufficienz am Beispiel der Hepatitis B Impfung. Klinische Wochenschrift 66: 865–872, 1988
Kumar SS, Ventura AK, Vanderuerf B. Influenza vaccination in renal transplant recipients. Journal of the American Medical Association 239: 840, 1978
Kunori T, Fehrman I, Ringden O, Muller E. In vitro characterization of immunological responsiveness of uraemic patients. Nephron 26: 234–239, 1980
Kurz P, Kohler H, Hutteroth M, Weleer M, Meyer zum Buschenfelde KH. Immune defect in the early stage of chronic renal failure. Proceedings of the European Dialysis and Transplant Association 22: 941–945, 1985
Kurz P, Kohler H, Mever SC, Hotteroth T, Meyer zum Buschenfelde KH. Impaired cellular immune response in chronic renal failure: evidence for a T cell defect. Kidney International 29: 1209–1214, 1986
Langhoff E, Hoffman B, Odun N, Ladefoged J, Platz P, et al. Kinetic analysis of interleukin 2 production and expression of interleukin 2 receptors by uraemic and normal lymphocytes. Scandinavian Journal of Immunology 25: 29–36, 1987
Langhoff E, Ladefoged J. Improved lymphocyte transformation in vitro of patients on continuous ambulatory peritoneal dialysis. Proceedings of the European Dailysis and Transplant Association 20: 230–235, 1983
Langhoff ED, Ladefoged J. Cellular immunity in renal failure: depression of lymphocyte transformation by uraemia and methylprednisolone. International Archives of Allergy and Applied Immunology 74: 241, 1984
Langhoff E, Ladefoged J. In vitro national killer and killer cell function in uraemia. International Archives of Allergy and Applied Immunology 78: 218, 1985
Lelie CPU, Reesink HW, le Jong STH. Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing haemodialysis. Archives of Internal Medicine 145: 305–309, 1985
Lindner A, Farewell UT, Sheppard DJ. High incidence of neoplasm in uraemic patients receiving long-term dialysis. Nephron 27: 292–296, 1981
Linneman Jr CC, First MR. Risk of pneumococcal infection in renal transplant patients. Journal of the American Medical Association 241: 2619–2621, 1979
Linneman Jr CC, First MR, Schiffman G. Response to pneumococcal vaccine in renal transplant and haemodialysis patients. Archives of Internal Medicine 141: 1637–1640, 1981
Linneman Jr CC, First MR, Schiffman G. Revaccination of renal transplant and haemodialysis recipients with pneumococcal vaccine. Archives of Internal Medicine 146: 1554–1556, 1986
London WT, Drew JS, Lustbader ED, Werner BG, Blumberg BS. Host responses to hepatitis B infection in patients in a chronic haemodialysis unit. Kidney International 12: 51–58, 1977
Lorton JE, Kiepela P, Coorvadia HM, Seedat YK. Suppressor cells assayed by numerical and functional tests in chronic renal failure. Kidney International 22: 192–197, 1982
Matas AJ, Simmons RL, Kjellstrand CM, Busselmeuer IJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet 1: 883–885, 1975
McIntosh J, Hansen P, Ziegler T, Perry R. Defective immune and phagocytic functions in uraemia and renal transplantation. International Archives of Allergy and Applied Immunology 51: 544–5491, 1976
Meuer SC, Dumam H, Meyer zum Buschenfelde KH, Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1: 15–18, 1989
Meuer SC, Hower M, Kurz P, Meyer zum Buschenfelde KH, Kohler H. Selective blockade of the antigen-receptor mediated pathway of T cell activation in patients with impaired primary immune responses. Journal of Clinical Investigations 80: 743–749, 1987
Meuer SC, Kohler H, Meyer zum Buschenfelde KH. Monocyte defect in haemodialysis patients supports non-responsiveness to hepatitis B vaccination and development of HBsAg carrier state. In Zuckerman (Ed.) Viral hepatitis and liver disease, pp. 711–713, Alan Liss Inc., New York, 1988
Meuer SC, Meyer zum Buschenfelde KH. T cell receptor triggering induces responsiveness to interleukin-1 and interleukin-2, but does not lead to T cell proliferation. Journal of Immunology 136: 4106–4112, 1986
Montgomerie JZ, Kalmanson GM, Guze LB. Renal failure and infection. Medicine 47: 1–32, 1968
Montgomerie JZ, Kalmanson GM, Guze LB. Leucocyte phagoctyosis and serum bactericidal activity in chronic renal failure. American Journal of the Medical Sciences 264: 385–393, 1972
Moyer LA, Alter MJ, Favero MS. Haemodialysis associated hepatitis B: revised recommendation for serologic screening. Seminars in Dialysis 3: 201–204, 1990
Mylson MA, Kraue HE, Schiffnon G. Long-term persistence of antibody following immunization with pneumococcal polysaccaride vaccine (41643). Proceedings of the Society for Experimental Biology and Medicine 173: 270–275, 1983
Najarian JS, Fryds DS, Stand M, Canafax DM, Ascher NL, et al. A single institution, randomized, prospective trial of cyclosporine versus azathioprine-antilymphoctye globulin for immunosuppression in renal allograft recipients. Annals of Surgery 201: 142–157, 1985
Nakamura A, Manser T, Pearson GDN, Daby MG, Gaftor M. Effect of interferon-gamma on the immune response in vivo and on gene expression in vitro. Nature 307: 381–382, 1984
Navarro J, Touraine JL, Corre C, Traeger J. Prolongation of skin allograft survival and inhibition of graft versus host reaction in rodents treated with ‘middle molecules’. Cellular Immunology 31: 149–154, 1977
Nelson DS, Penrose JM. Effect of haemodialysis and transplantation on inhibition of lymphocyte transformation by sera from uraemic patients. Clinical Immunology and Immunopathology 4: 143–146, 1975
Newberry WM, Sandford JP. Defective cellular immunity in renal failure: depression of reactivity of lymphoctyes to phytohaemagglutinin by renal failure serum. Journal of Clinical Investigation 50: 1262–1271, 1971
Nikoskelainen J, Koskela M, Forsstrom J, Kasaen M, Leindnen M. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney International 28: 671–677, 1985
Olmstead EG, Lunseth JH. Skin manifestations of chronic acidosis. Archives of Dermatology 77: 304, 1958
Onorato IM, Apelrod JL, Lorch LA, Brenoilver JM, Bokkenheuser V. Fungal infections of dialysis fistulae. Annals of Internal Medicine 91: 50–52, 1979
Osaki K, Ostuka H, Uomizu K, Harade R, Ostuyi Y, et al. Monocyte-mediated suppression of mitogen responses of lymphocytes in uraemic patients. Nephron 34: 87, 1983
Pabico CR, Douglas RG, Betts RF. Influenza vaccination of patients with glomerular disease. Annals of Internal Medicine 81: 171–177, 1974
Pabico RD, Douglas RG, Betts RF, McKenna BA, Freeman RB. Antibody response to influenza vaccination in renal transplant patients. Annals of Internal Medicine 85: 431, 1976
Pass RF, Whittley RJ, Diethelm AG, Whelchel JD, Reynolds DW, et al. Cytomegalovirus infection in patients with renal transplants: potentiation by antithymocyte globulin and an incompatible graft. Journal of Infectious Diseases 142: 9–17, 1980
Pattison CP. Hepatitis as a haemodialysis hazard. American Heart Journal 88: 386–387, 1974
Pillion G, Chiesa M, Mousin A, Schlegel, Loirat C. Immunogenicity of hepatitis B vaccine (HEVAC B) in children with advanced renal failure. Paediatric Nephrology 4: 627–629, 1990
Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, et al. Effect of Towne live virus on cytomegalovirus disease after renal transplant. Annals of Internal Medicine 114: 525–531, 1991
Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K. Vaccines for the prevention of human cytomegalovirus infection. Reviews of Infectious Diseases 12 (Suppl. 7): 5827–5838, 1990
Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in haemodialyzed patients. Journal of Hepatology 11: 385–387, 1990
Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC. Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. Clinical Nephrology 35: 198–206, 1991
Quadracci LJ, Ringden O, Krzymanski M. The effect of uraemia and transplantation on lymphocyte subpopulations. Kidney International 10: 179–184, 1976
Quiroga JA, Castillo I, Porres JC, Casado S, Saez F, et al. Recombinant-interferon as adjuvant to hepatitis vaccine in haemodialysis patients: influence of HCV. Hepatology 12: 661–663, 1990
Raska Jr K, Raskova J, Shea SM. T cell subsets and cellular immunity in end stage renal disease. American Journal of Medicine 75: 734–740, 1983
Raskova J, Ghobrial I, Shea SM, Ebert EC, Eisenger R, et al. T cells in patients undergoing chronic haemodialysis: mitogenic response, supressor activity and interleukin-2 production and receptor generation. Diagnostic Immunology 4: 208–215, 1986
Raskova J, Ghobrial I, Shea SM, Eisenger RP, Raska K. Suppressor cells in end-stage renal disease: functional assay and monoclonal antibody analysis. American Journal of Medicine 76: 847–853, 1984
Raskova J, Raska Jr K. Humoral inhibitor of the immune response in uraemia V: induction of suppressor cells in vitro by uraemic serum. American Journal of Pathology 111: 149–155, 1983
Rautenberg P, Proppe D, Schutte A, Ullman V. Influenza subtype-specific immunoglobulin A and G responses after booster vaccination versus one double dose vaccination in haemodialysis patients. European Journal of Clinical Microbiology and Infectious Diseases 8: 897–900, 1989
Reddy MM, Gok KO, Cesters RVM. T and B lymphoctyes in patients with chronic renal disease on haemodialysis. Experientia 31: 980–981, 1975
Regenstein FG, Perillo RP, Bodicsy C, Stern K, Zelman S. Clinical and immunologic features of chronic dialysis patients who fail to respond to hepatitis B vaccine. Vaccine 3: 27–30, 1985
Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of hepatitis B surface antigenaemia in haemodialysis patients. Archives of Internal Medicine 139: 178, 1979
Rubin RH, Tolkoff-Rubin NE, Oliver D, Rota TR, Hamilton J, et al. Multicentre seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 40: 243–249, 1985
Rutsky EA, Rostana SG. Mycobacteriosis in patients with chronic renal failure. Archives of Internal Medicine 140: 57–61, 1980
Rytel MW, Dailey MP, Schiffman G, Hoffman RG, Piering WF. Pneumococcal vaccine immunization of patients with renal impairment. Proceedings of the Society for Experimental Biology and Medicine 182: 468–473, 1986
Sanders Jr CV, Luby JP, Sandford JP, Hull AR. Suppression of interferon response in lymphoctyes from patients with uraemia. Journal of Laboratory and Clinical Medicine 77: 768–776, 1971
Scatizzi A, Strippoli P. Prevention of Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis. In Smeby et al. (Eds) Immune and metabolic aspects of blood purification systems, pp. 191–196, Karger, Basel 1986
Schwebke J, Miuais S. Vaccination in haemodialysis patients. International Journal of Artificial Organs 12: 481–484, 1989
Seaworth B, Drucker J, Starling J, Drucker R, Stevens G. Hepatitis B vaccines in patients with chronic renal failure before dialysis. Journal of Infectious Diseases 157: 332–337, 1988
Selroos O, Paternack A, Virolainen M. Skin test sensitivity and antigen-induced lymphocyte transformation in uraemia. Clinical Experiments in Immunology 14: 365–370, 1973
Sengar DPS, Rashid A, McLeish WA, Harris JE, Couture RA, et al. Hepatitis B surface antigen infection in a haemodialysis unit II: factors affecting host immune response to HBsAg. Canadian Medical Association Journal 113: 945–948, 1975
Simberkoff MS, Schiffman G, Katz LA, Spicehandler C, Moldover NH, et al. Pneumococcal capsular polysaccharide vaccination in adult chronic haemodialysis patients. Journal of Laboratory and Clinical Medicine 96: 363–370, 1980
Sinnesael JJ, Van Der Niejsen P, Verleesten DL. Treatment with recombinant human erythropoietin increases antibody titres after hepatitis B vaccination in dialysis patients. Kidney International 40: 121–128, 1991
Sipilsa R, Hortling L, Hervi T. Good seroresponse to enhanced-potency inactivated poliovirus vaccine in patients on chronic dialysis. Nephrology Dialysis Transplantation 5: 352–355, 1990
Slifkin RF, Goldberg J, Neff MS, Baeg A, Mattoo N. Malignancy in end-stage renal disease. Transactions of the American Society of Artificial Internal Organs 23: 34–39, 1977
Smiddy FG, Burwell RG, Parsons FM. Influence of uraemia on the survival of skin homografts. Nature 190: 732–734, 1961
Smit-Luis MBL, Kramer P, Heitjink RA, Hop WCJ, Schalm SW. Hepatitis B vaccination of haemodialysis patients: randomized control trial comparing plasma derived vaccine with and without pre-S2 antigen. European Journal of Clinical Investigation 20: 540–545, 1990
Smiley ML, Wlodover CG, Grossman RA, Barker CF, Perloff LJ, et al. The role of pretransplantation immunity in protection from cytomegalovirus disease following renal transplantation. Transplant 40: 157–161, 1985
Steketee RW, Ziarnik ME, Davis JP. Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centres, Wisconsin. American Journal of Epidemiology 127: 772–782, 1988
Snydman DR, Bryan JA, London WT. Transmission of Hepatitis B associated with haemodialysis: role of malfunction (blood leaks) in dialysis machines. Journal of Infectious Diseases 134: 562–570, 1976
Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, et al. Hepatitis B vaccine in patients receiving haemodialysis. New England Journal of Medicine 311: 496–501, 1984
Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fontino M. Hepatitis B vaccine: immune response in haemodialysis patients. Lancet 2: 1211, 1980
Stoloff IL, Stout R, Myerson RM, Howens WP. Production of antibody in patients with uraemia. New England Journal of Medicine 259: 320–323, 1958
Szmuness W, Neuroth R, Stevens CE, Strick N, Harley EJ. Prevalence of hepatitis B e antigen and its antibody in various HBsAg carrier populations. American Journal of Epidemiology 113: 113, 1981
Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, et al. Hepatitis B vaccine in medical staff of haemodialysis units: efficacy and subtype cross-protection. New England Journal of Medicine 307: 1481–1486, 1982
Touraine JL, Touraine JP, Revillard JP, Brochier J, Traegar T. T lymphoctyes and serum inhibitors of cell-mediated immunity in renal insufficiency. Nephron 14: 195–208, 1975
Van Geelen JA, Schalm SW, de Visser EM, Heitjink RA. Immune response to hepatitis B vaccine in haemodialysis patients. Nephron 45: 216–218, 1987
Versluis DJ, Beyer WEP, Masurel N, Diderich PPNM, Dramer P, et al. Intact humoral immune response in patients on continuous ambulatory peritoneal dialysis. Nephron 49: 16–19, 1988
Versluis DJ, Beyer WE, Masurel N, Weimar W, Didouich PP, et al. Value of booster immunisation with influenza vaccine in patients undergoing haemodialysis. British Medical Journal 294: 348, 1987
Versluis DJ, Beyer WEP, Masurel N, Wenting GJ. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 42: 376–379, 1986
Wainwright RB, McMahon BJ, Bulkow LR, Hall DB, Fitzgerald MA, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. Journal of the American Medical Association 261: 2362–2366, 1989
Walz G, Kunzendorf U, Haller H, Keller F, Offermann G, et al. Factors influencing the response to hepatitis B vaccination of haemodialysis patients. Nephron 51: 474–477, 1989
Waymack JP, Conce S, Miskall P, Alexander JW. Mechanisms of action of two new immunomodulators. Archives of Surgery 120: 43–48, 1985
West DJ. Clinical experience with hepatitis B vaccines. American Journal of Infection Control 17: 172–189, 1989
West TE, Walse JJ, Krol CP, Amsterdam D. Staphylococcal peritonitis in patients on CAPD. Journal of Clinical Microbiology 23: 8109–8112, 1986
Wilson WEC, Kirkpatrick CH, Talmage DW. Suppression of immunologic responsiveness in uraemia. Annals of Internal Medicine 62: 1–14, 1965
Winer RL, Ellis MH, Cesario TC, Mirahmadi KS, Tilles JG. Swine influenza vaccination in transplant and dialysis patients. Dialysis and Transplantation 7: 207, 1978
Zarubak, Grob PJ, Bolla K. Thymopentin as adjuvant therapy to Hepatitis B vaccination in formerly non- or hyporesponding haemodialysis patients. Surveys of Immunologic Research 4 (Suppl. 1): 102–106, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnson, D.W., Fleming, S.J. The Use of Vaccines in Renal Failure. Clin. Pharmacokinet. 22, 434–446 (1992). https://doi.org/10.2165/00003088-199222060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199222060-00003